11/20
08:06 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/14
11:23 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $25.00 to $23.00. They now have a "buy" rating on the stock.
11/13
02:26 am
zvra
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Medium
Report
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
11/12
04:14 pm
zvra
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]
Low
Report
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates [Yahoo! Finance]
11/12
04:05 pm
zvra
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
Medium
Report
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
11/11
04:42 pm
zvra
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting [Yahoo! Finance]
Low
Report
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting [Yahoo! Finance]
11/11
04:36 pm
zvra
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
Medium
Report
Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
11/11
07:33 am
zvra
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Low
Report
Zevra Therapeutics Inc (ZVRA) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/6
07:30 am
zvra
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
Medium
Report
Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
10/31
07:30 am
zvra
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
Medium
Report
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
10/11
01:50 pm
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/10
07:30 am
zvra
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
Medium
Report
Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
10/9
09:00 am
zvra
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders
Low
Report
NUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders
10/7
09:01 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at Guggenheim. They set a "buy" rating and a $20.00 price target on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at Guggenheim. They set a "buy" rating and a $20.00 price target on the stock.
10/4
12:15 pm
zvra
Zevra Stock Surges Close to 70% in 3 Months: Here's Why [Yahoo! Finance]
Low
Report
Zevra Stock Surges Close to 70% in 3 Months: Here's Why [Yahoo! Finance]
10/1
08:46 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/30
08:01 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
9/25
07:09 am
zvra
Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year [Yahoo! Finance]
Medium
Report
Investors in Zevra Therapeutics (NASDAQ:ZVRA) have seen decent returns of 67% over the past year [Yahoo! Finance]
9/24
09:14 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Roth Mkm from $19.00 to $21.00. They now have a "buy" rating on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Roth Mkm from $19.00 to $21.00. They now have a "buy" rating on the stock.
9/24
08:42 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $17.00 price target on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is now covered by analysts at JMP Securities. They set an "outperform" rating and a $17.00 price target on the stock.
9/24
08:06 am
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Maxim Group from $18.00 to $25.00. They now have a "buy" rating on the stock.
Medium
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at Maxim Group from $18.00 to $25.00. They now have a "buy" rating on the stock.
9/24
07:30 am
zvra
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
Medium
Report
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024
9/20
01:29 pm
zvra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Zevra Therapeutics, Inc. (NASDAQ: ZVRA) had its price target raised by analysts at HC Wainwright from $18.00 to $20.00. They now have a "buy" rating on the stock.
9/20
12:24 pm
zvra
Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C [Yahoo! Finance]
Medium
Report
Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C [Yahoo! Finance]
9/20
12:08 pm
zvra
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
Medium
Report
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C